← Back to Clinical Trials
Recruiting NCT06471387

NCT06471387 Unraveling the Genetic Basis of Nicotine Addiction for Novel Therapeutic Strategies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06471387
Status Recruiting
Phase
Sponsor University of Cyprus
Condition Smoking Cessation
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2023-11-01
Primary Completion 2025-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type OBSERVATIONAL
Interventions
Flexiquit Smoking Cessation Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2023-11-01 with a primary completion date of 2025-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This case-control study aims to investigate the genetic and molecular bases of nicotine addiction to identify potential therapeutic targets. The project will involve drug repurposing using Mendelian Randomization, a smoking cessation intervention, and the analysis of methylation status in participants undergoing nicotine withdrawal.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18-60 years old * Current daily cigarette smoker * Able to understand study procedures and provide informed consent * For females, non-pregnant and non-lactating Exclusion Criteria: * Presence of significant uncontrolled medical conditions (e.g. cardiovascular disease, respiratory disorders, cancer) that could affect smoking behaviors or study participation * Presence of major uncontrolled psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe depression) * Current substance use disorder (except nicotine dependence) * Taking medications that could significantly interfere with study objectives (e.g. medications for smoking cessation) * Significant cognitive impairment that precludes ability to complete study procedures

Contact & Investigator

Central Contact

Andrea N Georgiou, Ph.D.

✉ georgiou.andrea@ucy.a.cy

📞 (+357)-22893372

Frequently Asked Questions

Who can join the NCT06471387 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06471387 currently recruiting?

Yes, NCT06471387 is actively recruiting participants. Contact the research team at georgiou.andrea@ucy.a.cy for enrollment information.

Where is the NCT06471387 trial being conducted?

This trial is being conducted at Nicosia, Cyprus.

Who is sponsoring the NCT06471387 clinical trial?

NCT06471387 is sponsored by University of Cyprus. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology